Effect of graft cell dose on second transplantation from a haploidentical donor with post-transplantation cyclophosphamide for relapsed/refractory acute leukemia-Reference-Cited by-同舟云学术

Effect of graft cell dose on second transplantation from a haploidentical donor with post-transplantation cyclophosphamide for relapsed/refractory acute leukemia

Published:2023-04-28 Issue:8 Volume:58 Page:947-949
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Nakaya Yosuke^ORCID,Nakamae Hirohisa^ORCID,Harada Naonori,Okamura Hiroshi,Sakatoku Kazuki,Ido Kentaro,Makuuchi Yosuke,Kuno Masatomo^ORCID,Takakuwa Teruhito,Hirose Asao,Nakamae Mika^ORCID,Nishimoto Mitsutaka,Nakashima Yasuhiro^ORCID,Koh Hideo,Hino Masayuki

Funder

MEXT | Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01986-6.pdf

Reference12 articles.

1. Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B, et al. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2021;56:2194–202.

2. Kharfan-Dabaja MA, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021;193:592–601.

3. Maffini E, Labopin M, Blaise D, Ciceri F, Gulbas Z, Deconinck E, et al. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2020;95:892–9.

4. Yokoyama Y, Maie K, Fukuda T, Uchida N, Mukae J, Sawa M, et al. A high CD34(+) cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. Bone Marrow Transpl. 2020;55:1726–35.

5. Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, et al. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transpl. 2021;56:1683–90.